Generic Allegra Availability

Allegra is a brand name of fexofenadine, approved by the FDA in the following formulation(s):

ALLEGRA (fexofenadine hydrochloride - suspension;oral)

Has a generic version of Allegra been approved?

A generic version of Allegra has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Allegra and have been approved by the FDA:

fexofenadine hydrochloride suspension;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Allegra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Piperidine derivatives
    Patent 5,578,610
    Issued: November 26, 1996
    Inventor(s): D'Ambra; Thomas E.
    Assignee(s): Albany Molecular Research, Inc.
    The present invention relates to substantially pure piperidine derivative compounds of the formulae: ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; R.sub.3 is --COOH or --COOR.sub.4 ; R.sub.4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.
    Patent expiration dates:
    • November 26, 2013
      ✓ 
      Patent use: USE IN TREATING ALLERGIC REACTIONS
    • November 26, 2013
      ✓ 
      Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • May 26, 2014
      ✓ 
      Pediatric exclusivity
  • Pharmaceutical composition for piperidinoalkanol compounds
    Patent 5,738,872
    Issued: April 14, 1998
    Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marquerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
    Assignee(s): Hoechst Marion Roussel, Inc.
    The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Patent expiration dates:
    • February 28, 2015
    • August 28, 2015
      ✓ 
      Pediatric exclusivity
  • Pharmaceutical compositions for piperidinalkanol compounds
    Patent 5,855,912
    Issued: January 5, 1999
    Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marguerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
    Assignee(s): Hoechst Marion Roussel, Inc.
    The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Patent expiration dates:
    • February 28, 2015
    • August 28, 2015
      ✓ 
      Pediatric exclusivity
  • Pharmaceutical composition for piperidinoalkanol compounds
    Patent 5,932,247
    Issued: August 3, 1999
    Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marguerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
    Assignee(s): Hoechst Marion Roussel, Inc.
    The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Patent expiration dates:
    • February 28, 2015
    • August 28, 2015
      ✓ 
      Pediatric exclusivity
  • Method of providing an antihistaminic effect in a hepatically impaired patient
    Patent 6,037,353
    Issued: March 14, 2000
    Inventor(s): Woodward; James K. & Okerholm; Richard A. & Eller; Mark G. & McNutt; Bruce E.
    Assignee(s): Hoechst Marion Roussel, Inc.
    The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; n is an integer of from 1 to 5; R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
    Patent expiration dates:
    • March 14, 2017
      ✓ 
      Patent use: TREATMENT OF ALLERGIC RHINITIS
    • March 14, 2017
      ✓ 
      Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
    • September 14, 2017
      ✓ 
      Pediatric exclusivity
  • Pharmaceutical composition for piperidinoalkanol compounds
    Patent 6,113,942
    Issued: September 5, 2000
    Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marguerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
    Assignee(s): Aventis Pharmaceuticals Inc.
    The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Patent expiration dates:
    • February 28, 2015
    • August 28, 2015
      ✓ 
      Pediatric exclusivity
  • Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
    Patent 7,135,571
    Issued: November 14, 2006
    Inventor(s): Henton; Daniel R & McCarty; Frederick J & Tripp; Susan I & DeWitt; Jill E
    Assignee(s): Aventis Pharmaceuticals, Inc.
    The present invention is related to novel processes for preparing anhydrous and hydrated forms of piperidine derivatives, polymorphs and pseudomorphs thereof of the formulas which are useful as antihistamines, antiallergic agents and bronchodilators.
    Patent expiration dates:
    • May 18, 2014
      ✓ 
      Drug substance
    • November 18, 2014
      ✓ 
      Pediatric exclusivity
  • Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
    Patent 7,138,524
    Issued: November 21, 2006
    Inventor(s): McCarty; Frederick J. & Carr; Albert A.
    Assignee(s): Aventis Pharmaceuticals, Inc.
    The present invention is related to novel processes for preparing anhydrous and hydrated forms of piperidine derivatives, polymorphs and pseudomorphs thereof of the formulas which are useful as antihistamines, antiallergic agents and bronchodilators.
    Patent expiration dates:
    • May 18, 2014
      ✓ 
      Drug substance
    • November 18, 2014
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web1)